Back

Phenotyping of patients with pulmonary hypertension and mean pulmonary arterial pressure between 21 and 24 MMHG

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary arterial hypertension: general (2) Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Francesco Cennerazzo

S. Orsola-Malpighi Policlinic, Bologna (Italy)

7 More presentations in this session

Presentation thumbnail
Temporal trends in the incidence and mortality of pulmonary arterial hypertension in the United Kingdom over the past 3 decades
Doctor Z. Abdulelah (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Venus excess lung ultrasound (VExUS) score for the estimation of right atrial pressure
Professor M. D'Alto (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension and pregnancy. Experience in Argentina (ARGEN-HP)
Doctor L. Lema (Cordoba, AR)
Abstract Slides Video
Presentation thumbnail
Recruitment of major aorto-pulmonary collateral arteries across pulmonary hypertension groups and its clinical significance
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Association of baseline newer and established cardiopulmonary exercise test parameters with precapillary pulmonary hypertension severity and survival, a nine year follow-up study
Doctor H. Triantafyllidi (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary arterial hypertension: general (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Prognosis and clinical characteristics of mild pulmonary hypertension under the updated haemodynamic criteria
thumbnail
Congress Presentation
Mapping right ventricular adaptation in pulmonary arterial hypertension: insights from a six-phenotype model
thumbnail
Congress Presentation
Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources